NCT06999187

A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

A Phase 1a/1b, Multicenter, Open-label, Dose Escalation/Expansion, Multiple-dose Study to Evaluate the Safety and Activity of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 96 (estimated)
• Sponsor: Dren Bio · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas

Conditions

• Triple Negative Breast Cancer
• HER2-negative Breast Cancer
• Non Small Cell Lung Cancer
• Cervical Cancer
• Castrate Resistant Prostate Cancer
• Pancreatic Ductal Adenocarcinoma
• Head-and-neck Squamous Cell Carcinoma
• Endometrial Cancer
• Ovarian Cancer
• Gastric Cancer
• Gastroesophageal-junction Cancer
• Urothelial Carcinoma

Interventions

Type	Name	Description
DRUG	DR-0202	DR-0202 is a bispecific antibody

Timeline

• Start date: 2025-06-03
• Primary completion: 2027-07-01
• Completion: 2027-12-01
• First posted: 2025-05-31
• Last updated: 2026-01-07

Locations

10 sites across 1 country: United States

Regulatory

• FDA-regulated drug study